Two Sigma Securities, LLC Crispr Therapeutics Ag Put Options Transaction History

Two Sigma Securities, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$44.62 - $62.75 $1.12 Million - $1.57 Million	-25,000 Reduced 85.32%	4,300 $202,000
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $757,316 - $1.01 Million	14,800 Added 102.07%	29,300 $1.58 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $1.37 Million - $2.01 Million	-22,600 Reduced 60.92%	14,500 $988,000
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $1.04 Million - $1.94 Million	26,900 Added 263.73%	37,100 $2.32 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $195,177 - $253,700	4,300 Added 72.88%	10,200 $462,000
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $256,473 - $399,843	5,900 New	5,900 $331,000
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $650,554 - $1.09 Million	-16,600 Reduced 50.46%	16,300 $662,000
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $1.47 Million - $2.02 Million	24,100 Added 273.86%	32,900 $2.15 Million
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $155,628 - $265,788	-3,600 Reduced 29.03%	8,800 $535,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $659,556 - $982,575	12,400 New	12,400 $778,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.